KRAS and non-small cell lung carcinoma: While there have been recent breakthroughs in targeting KRAS G12C in NSCLC and KRAS G12D in pancreatic cancer, there is yet to be a KRAS G12V-specific compound, and there is an unmet clinical need for strategies to target this tumor subtype.